Viatris raises 2026 outlook while targeting $500M peak sales for fast-acting meloxicam

Viatris has raised its 2026 outlook and reported solid results with second-quarter revenue of $3.8 billion.

AI CATALYST SCORE78 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

ANALYSIS HISTORY

VTRS Analysis History (Last 30 Days)

Diagnosed At	Ticker	AI Score	Tier
2026-08-28 09:43:13	VTRS	75	Mid	View Report →
2026-08-06 23:49:53	VTRS	78	Mid	View Report →
2026-08-06 11:44:10	VTRS	80	Mid	View Report →

RELATED REPORTS

Diagnosed At	Ticker	AI Score	Tier
2026-08-29 05:44:07	MRNA	85	Mid	View Report →
2026-08-28 20:33:58	ZBH	75	Mid	View Report →
2026-08-28 11:27:16	LLY	85	Mid	View Report →
2026-08-28 11:19:33	MRNA	40	Row	View Report →
2026-08-27 18:58:14	WAT	85	Mid	View Report →
2026-08-27 07:08:21	AZN	85	Mid	View Report →
2026-08-26 21:15:44	ALC	45	Row	View Report →
2026-08-26 18:15:47	GSK	82	Mid	View Report →
2026-08-26 16:23:43	TRUP	40	Row	View Report →
2026-08-26 15:04:41	NEOG	75	Mid	View Report →
2026-08-26 14:49:54	TARS	75	Mid	View Report →
2026-08-26 14:14:46	ARGX	85	S-Class	View Report →
2026-08-26 12:52:37	GSK	75	Mid	View Report →
2026-08-26 11:33:57	LLY	85	Mid	View Report →
2026-08-26 08:30:32	NEOG	85	S-Class	View Report →
2026-08-26 08:30:23	TRUP	45	Row	View Report →
2026-08-25 14:26:29	MRNA	90	S-Class	View Report →
2026-08-25 14:21:10	LLY	40	Row	View Report →
2026-08-25 13:22:05	LLY	75	Mid	View Report →
2026-08-25 12:57:21	MCK	85	S-Class	View Report →
2026-08-25 10:34:43	MRK	85	S-Class	View Report →
2026-08-25 10:05:37	MRNA	75	Mid	View Report →
2026-08-25 07:13:30	AVAH	40	Row	View Report →
2026-08-25 07:13:28	AVAH	40	Row	View Report →
2026-08-25 00:02:12	AVAH	40	Row	View Report →
2026-08-24 17:17:01	MRNA	85	S-Class	View Report →
2026-08-24 16:11:14	LLY	75	Mid	View Report →
2026-08-24 15:20:12	ARGX	40	Row	View Report →
2026-08-24 09:28:08	GSK	75	Mid	View Report →
2026-08-23 11:45:23	CSTL	85	S-Class	View Report →